A New Pill Could End the 30‑Year Drought of Oral Hair‑Loss Drugs

For most of us who have watched the hairline recede like a slow‑moving tide, the only prescription‑only hope was a topical foam or spray. That narrative is about to shift. Veradermics, a biotech firm that’s been quietly working on a new twist on an old drug, just announced eye‑popping results from its Phase III trial of VDPHL01, an extended‑release oral minoxidil pill.

Minoxidil isn’t new – you’ve probably seen it on store shelves under the Rogaine brand or as a generic liquid. Traditionally it’s applied to the scalp, which can be messy, sometimes itchy, and, if you have a curious cat or dog, a potential poison hazard. In recent years, a few dermatologists started prescribing tiny doses of oral minoxidil off‑label for hair loss, but no pill has ever cleared the FDA for that use.

Enter VDPHL01. The company says it’s a proprietary, low‑dose, extended‑release version of the drug that steadies the bloodstream level enough to keep hair follicles happy while staying well below the thresholds that trigger cardiovascular side effects. In plain English: you take a pill once (or twice) a day, and you’re less likely to get the scalp irritation you’d see with a foam.

The data look convincing. In a double‑blind, placebo‑controlled study of roughly 500 men with mild‑to‑moderate androgenetic alopecia, 55 % of participants taking the once‑daily regimen reported “improved” or “much improved” hair coverage after six months, versus just 15 % on placebo. The twice‑daily group fared even better, with 68 % seeing similar gains. Both groups also posted a solid bump in non‑vellus (real) hair count compared with the control arm.

Safety mattered as much as efficacy. No severe adverse events or heart‑related issues popped up. A small slice – under 10 % – experienced hypertrichosis, meaning extra hair grew on other body parts, but fewer than 1 % stopped the medication because of it. In short, the pill was well tolerated.

Why does this matter? The last time the FDA green‑lit a new oral hair‑loss drug was back in the 1990s, and that option was hormonal. VDPHL01 would be the first non‑hormonal oral therapy approved for male pattern baldness in almost three decades. And Veradermics isn’t stopping at men; a parallel Phase III trial in women is already underway, with results slated for early next year.

Pricing is still a question mark, but the company points to Nutrafol – a popular hair‑growth supplement that runs about $90 a month – as a benchmark. If VDPHL01 lands in pharmacies at a comparable price, it could become the go‑to solution for anyone tired of the daily spray routine.

Other players are also in the race, developing their own hair‑loss candidates, but for now VDPHL01 looks poised to claim the headline. If the FDA signs off, the era of the oral hair‑loss pill may finally be here.